Abstract:Idiopathic Pulmonary Fibrosis (IPF) is characterized by progressive fibrosis and chronic lung tissue remodeling with a 3-5-year median patient survival, post-diagnosis. Overproduction of extracellular matrix (ECM) by activated myofibroblasts as a result of cytokines like transforming growth factor β (TGFβ) is a key feature of IPF. Novel antifibrotics are urgently needed since the approved therapies only slow down disease progression. We took a top-down approach to drug discovery, conducting high-content drug screenings & structure-activity relationship (SAR) studies leading to the discovery of a new class of potent antifibrotics N-(2-butoxyphenyl)-3-phenyl)acrylamides (N23Ps). For lead development, we conducted a comprehensive SAR analysis on N23P-derivatives using high-content ECM deposition assays with primary IPF-derived lung fibroblasts. Here, collagen V & fibulin-1 deposition by these fibroblasts were measured against varying concentrations of N23Ps. Biological and technical replicates across 115 experiments with 142 compounds and varying degrees of structural alterations led to a complex set of dose-response data. To address the complexity and to automate the analysis, we developed metaSAR, a computational pipeline to estimate compound activities and characteristics from dose-response curves while considering outliers, edge effects, and plate & curve quality. Using cheminformatic tools and regression models, we could successfully identify chemical groups and locations associated with potency which ultimately led to highly potent & stable N23P derivates. To elucidate their effects on the lung microenvironment, we are now conducting single-cell RNA sequencing on perturbed human precision-cut lung slices.

Discovery of the Novel, Orally Active, and Selective LPA1 Receptor Antagonist ACT-1016-0707 as a Preclinical Candidate for the Treatment of Fibrotic Diseases

Discovery of a Novel Orally Active, Selective LPA Receptor Type 1 Antagonist, 4-(4-(2-Isopropylphenyl)-4-((2-methoxy-4-methylphenyl)carbamoyl)piperidin-1-yl)-4-oxobutanoic Acid, with a Distinct Molecular Scaffold

Lead optimization and mode-of-action elucidation for novel antifibrotics

Discovery, Cocrystallization and Biological Evaluation of Novel Piperidine Derivatives As High Affinity Ls-AChBP Ligands Possessing Α7 Nachr Activities.

Design, synthesis, and biological evaluation of piperazine derivatives as pan-PPARs agonists for the treatment of liver fibrosis

Combined 3D-QSAR, molecular docking and molecular dynamics simulation study on pyrazole-and triazole-derived carbamates as LPAR1 antagonists

The Discovery of MORF-627, a Highly Selective Conformationally-Biased Zwitterionic Integrin αvβ6 Inhibitor for Fibrosis

Discovery of 3,4,6-Trisubstituted Piperidine Derivatives As Orally Active, Low Herg Blocking Akt Inhibitors Via Conformational Restriction and Structure-Based Design

Discovery and Development of Highly Potent and Orally Bioavailable Nonpeptidic αvβ6 Integrin Inhibitors

Discovery of 1,8-naphthalidine derivatives as potent anti-hepatic fibrosis agents via repressing PI3K/AKT/Smad and JAK2/STAT3 pathways

Extended Structure–Activity Relationship and Pharmacokinetic Investigation of (4-Quinolinoyl)glycyl-2-cyanopyrrolidine Inhibitors of Fibroblast Activation Protein (FAP)

Discovery of 6-[(3 S,4 S)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a Potent and Orally Bioavailable SHP2 Inhibitor

Lead generation from N-[benzyl(4-phenylbutyl)carbamoyl]amino acid as a novel LPA1 antagonist for the treatment of systemic sclerosis

Isoquinolone derivatives as lysophosphatidic acid receptor 5 (LPA5) antagonists: Investigation of structure-activity relationships, ADME properties and analgesic effects

Design, synthesis, and biological evaluation of novel pyrrolidinone small-molecule Formyl peptide receptor 2 agonists

Lysophospholipid receptors in drug discovery

Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1)

Discovery of Selective PDE1 Inhibitors with Anti-pulmonary Fibrosis Effects by Targeting the Metal Pocket

Discovery of MT-1207: A Novel, Potent Multitarget Inhibitor as a Promising Clinical Candidate for the Treatment of Hypertension

Discovery of a series of 1,3,4-oxadiazole-2(3H)-thione derivatives containing piperazine skeleton as potential FAK inhibitors.

Mangostanin Derivatives as Novel and Orally Active Phosphodiesterase 4 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis with Improved Safety